Lisanti Capital Growth LLC Takes $3.95 Million Position in Guardant Health, Inc. $GH

Lisanti Capital Growth LLC acquired a new stake in shares of Guardant Health, Inc. (NASDAQ:GH) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 38,665 shares of the company’s stock, valued at approximately $3,949,000.

Several other institutional investors and hedge funds have also recently made changes to their positions in GH. V Square Quantitative Management LLC purchased a new position in Guardant Health in the 4th quarter worth $27,000. Chesapeake Asset Management LLC purchased a new position in Guardant Health in the 4th quarter worth $28,000. Thurston Springer Miller Herd & Titak Inc. purchased a new position in Guardant Health in the 4th quarter worth $31,000. Elyxium Wealth LLC purchased a new position in Guardant Health in the 4th quarter worth $35,000. Finally, First Pacific Financial purchased a new position in Guardant Health in the 4th quarter worth $43,000. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on GH shares. JPMorgan Chase & Co. lifted their target price on shares of Guardant Health from $130.00 to $135.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. Leerink Partners lifted their target price on shares of Guardant Health from $170.00 to $180.00 and gave the stock an “outperform” rating in a research report on Friday, February 20th. UBS Group reiterated a “buy” rating and issued a $175.00 target price on shares of Guardant Health in a research report on Friday, January 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Guardant Health in a research report on Tuesday, April 21st. Finally, Wells Fargo & Company lifted their target price on shares of Guardant Health from $120.00 to $125.00 and gave the stock an “overweight” rating in a research report on Friday, February 20th. Nineteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $129.00.

Guardant Health Trading Up 0.8%

GH stock opened at $118.95 on Friday. The firm’s 50-day moving average price is $91.15 and its two-hundred day moving average price is $98.94. Guardant Health, Inc. has a 12-month low of $36.36 and a 12-month high of $121.01. The stock has a market capitalization of $15.77 billion, a price-to-earnings ratio of -35.09 and a beta of 1.48.

Guardant Health (NASDAQ:GH) last released its quarterly earnings data on Thursday, February 19th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.07). The business had revenue of $281.27 million for the quarter, compared to analysts’ expectations of $269.74 million. During the same quarter last year, the firm earned ($0.62) EPS. The company’s revenue for the quarter was up 39.4% on a year-over-year basis. Equities analysts predict that Guardant Health, Inc. will post -2.92 EPS for the current year.

Insider Transactions at Guardant Health

In other Guardant Health news, Director Ian T. Clark sold 6,876 shares of the business’s stock in a transaction dated Wednesday, May 20th. The shares were sold at an average price of $106.90, for a total value of $735,044.40. Following the transaction, the director owned 2,975 shares in the company, valued at approximately $318,027.50. The trade was a 69.80% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Michael Brian Bell sold 3,000 shares of the business’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $87.04, for a total transaction of $261,120.00. Following the completion of the transaction, the chief financial officer owned 43,601 shares in the company, valued at $3,795,031.04. The trade was a 6.44% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 296,838 shares of company stock valued at $31,878,906. Company insiders own 5.60% of the company’s stock.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.